Key result
A2A-adenosine receptor activation with ATL146e reduced infarct size to 42.5% and 39.3% of the risk region at 5 and 10 microg/kg, respectively, compared with 61.0% in vehicle-treated mice (P<0.05).
Why the study?
Does ATL146e reduce infarct size in mouse models of myocardial ischemia-reperfusion injury?
Does ATL146e reduce infarct size in mouse models of myocardial ischemia-reperfusion injury?
Absolute Event Rate: 42.5% vs 61%
p-value: p=<0.05
A2A-adenosine receptor activation reduces myocardial infarct size and inflammation primarily through its action on bone marrow-derived lymphocytes.
No takes yet. Share an insight, caveat, or question.
Supports A2A agonism for infarct size reduction in mice; leaves open translation to human ischemia-reperfusion injury.
Yang et al. (2005) studied Myocardial infarction. ATL146e vs. Vehicle was evaluated on Infarct size as a percentage of risk region (p=<0.05). A2A-adenosine receptor activation with ATL146e reduced infarct size to 42.5% and 39.3% of the risk region at 5 and 10 microg/kg, respectively, compared with 61.0% in vehicle-treated mice (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: